Format

Send to

Choose Destination
Future Oncol. 2018 Apr;14(9):877-889. doi: 10.2217/fon-2017-0468. Epub 2018 Mar 26.

Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTEC.

Author information

1
CH Belfort-Montbéliard, Department of Radiation Therapy, Boulevard du Maréchal Juin, 25209 Montbéliard, France.
2
GORTEC, Hôpital Bretonneau, 2 Boulevard Tonnellé, 37044 Tours, France.
3
CHU - Normandie Université, Department of Head & Neck Surgery, 14000 Caen, France.
4
Center François Baclesse - Normandie Université, Department of Head & Neck Surgery, 3 Avenue Général Harris, 14000 Caen, France.
5
Center François Baclesse - Normandie Université, Department of Radiation Therapy, 3 Avenue Général Harris, 14000 Caen, France.
6
CHUV. Lausanne, Department of Radio-oncology, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland.

Abstract

Median survival for recurrent/metastatic head and neck squamous cell cancer (HNSCC) patients is about 10 months after first-line best systemic treatment. We aimed to assess current approaches of oligometastatic HNSCC patients by the analysis of current concept and published data (1995-2017) in this population. Five-year survival rates are over 20% in selected patients who undergo metastasis-directed therapy by either surgery or stereotactic irradiation. Human papillomavirus(+) HNSCC patients have more disseminated metastases but respond more favorably and also benefit from ablative treatments. Treatments of oligometastases are expanding rapidly. Unmet needs include revised imaging follow-up strategies to detect metastases earlier, identification of predictive noninvasive biomarkers for treatment guidance, assessment and corrections of biases in current studies and randomized clinical trials.

KEYWORDS:

ablative treatment; head and neck cancer; immunotherapy; metastasectomy; metastases; metastasis-directed treatment; oligometastases; stereotactic irradiation

PMID:
29578359
DOI:
10.2217/fon-2017-0468
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center